Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Unity Biotechnology Inc (NASDAQ:UBX) has announced positive data from its Phase 1 safety study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) for whom anti-VEGF therapy was no longer considered beneficial.
- UBX1325 is a small molecule inhibitor of Bcl-xL and was well-tolerated with no treatment-related adverse events or dose-limiting toxicities.
- Additionally, the majority of DME and wet AMD patients treated with a single injection of UBX1325 demonstrated rapid improvements in best-corrected visual acuity, central subfield thickness, and sub- and intra-retinal fluid, all key clinical measures of disease progression.
- The first patient has been dosed in Phase 2a study to assess the safety and efficacy of UBX1325 in a broader population of DME patients. Data is expected in the first half of 2022.
- UNITY will host a conference call and webcast today at 8:00 a.m. ET to discuss the UBX1325 clinical data.
- Price Action: UBX shares are up 14.1% at $5.10 during the premarket session on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!